262 related articles for article (PubMed ID: 34850906)
1. Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.
Clay MR; Pinto EM; Fishbein L; Else T; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2022 Mar; 107(4):1159-1169. PubMed ID: 34850906
[TBL] [Abstract][Full Text] [Related]
2. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
3. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular prognostic factors in adrenocortical carcinoma.
Libé R
Minerva Endocrinol; 2019 Mar; 44(1):58-69. PubMed ID: 30221891
[TBL] [Abstract][Full Text] [Related]
5. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
6. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
Bussey KJ; Demeure MJ
Future Oncol; 2009 Jun; 5(5):641-55. PubMed ID: 19519204
[TBL] [Abstract][Full Text] [Related]
7. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
Puglisi S; Perotti P; Cosentini D; Roca E; Basile V; Berruti A; Terzolo M
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1125-1133. PubMed ID: 30117750
[TBL] [Abstract][Full Text] [Related]
8. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management.
Ahmed AA; Thomas AJ; Ganeshan DM; Blair KJ; Lall C; Lee JT; Morshid AI; Habra MA; Elsayes KM
Abdom Radiol (NY); 2020 Apr; 45(4):945-963. PubMed ID: 31894378
[TBL] [Abstract][Full Text] [Related]
9. Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers.
Cheng Y; Kou W; Zhu D; Yu X; Zhu Y
Front Endocrinol (Lausanne); 2021; 12():811293. PubMed ID: 35178030
[TBL] [Abstract][Full Text] [Related]
10. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
J Cell Mol Med; 2021 Nov; 25(21):10061-10072. PubMed ID: 34664400
[TBL] [Abstract][Full Text] [Related]
11. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.
Landwehr LS; Altieri B; Schreiner J; Sbiera I; Weigand I; Kroiss M; Fassnacht M; Sbiera S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474412
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Adrenocortical Carcinoma.
Vaidya A; Nehs M; Kilbridge K
Surg Pathol Clin; 2019 Dec; 12(4):997-1006. PubMed ID: 31672303
[TBL] [Abstract][Full Text] [Related]
13. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
14. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
15. Approach to the patient with adrenocortical carcinoma.
Lacroix A
J Clin Endocrinol Metab; 2010 Nov; 95(11):4812-22. PubMed ID: 21051577
[TBL] [Abstract][Full Text] [Related]
16. Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.
Sbiera S; Sbiera I; Ruggiero C; Doghman-Bouguerra M; Korpershoek E; de Krijger RR; Ettaieb H; Haak H; Volante M; Papotti M; Reimondo G; Terzolo M; Luconi M; Nesi G; Mannelli M; Libé R; Ragazzon B; Assié G; Bertherat J; Altieri B; Fadda G; Rogowski-Lehmann N; Reincke M; Beuschlein F; Fassnacht M; Lalli E
J Clin Endocrinol Metab; 2017 Sep; 102(9):3491-3498. PubMed ID: 28911143
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
18. PERSONALIZED CARE OF PATIENTS WITH ADRENOCORTICAL CARCINOMA: A COMPREHENSIVE APPROACH.
Miller BS; Else T;
Endocr Pract; 2017 Jun; 23(6):705-715. PubMed ID: 28614035
[TBL] [Abstract][Full Text] [Related]
19. Pediatric adrenocortical carcinoma.
Ilanchezhian M; Varghese DG; Glod JW; Reilly KM; Widemann BC; Pommier Y; Kaplan RN; Del Rivero J
Front Endocrinol (Lausanne); 2022; 13():961650. PubMed ID: 36387865
[TBL] [Abstract][Full Text] [Related]
20. ENDOCRINE TUMOURS: The genomics of adrenocortical tumors.
Faillot S; Assie G
Eur J Endocrinol; 2016 Jun; 174(6):R249-65. PubMed ID: 26739091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]